Mohammad Jahanzeb

3.3k total citations · 1 hit paper
69 papers, 1.7k citations indexed

About

Mohammad Jahanzeb is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Mohammad Jahanzeb has authored 69 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 58 papers in Oncology, 42 papers in Pulmonary and Respiratory Medicine and 12 papers in Cancer Research. Recurrent topics in Mohammad Jahanzeb's work include Lung Cancer Treatments and Mutations (34 papers), Lung Cancer Research Studies (18 papers) and Cancer Treatment and Pharmacology (16 papers). Mohammad Jahanzeb is often cited by papers focused on Lung Cancer Treatments and Mutations (34 papers), Lung Cancer Research Studies (18 papers) and Cancer Treatment and Pharmacology (16 papers). Mohammad Jahanzeb collaborates with scholars based in United States, France and United Kingdom. Mohammad Jahanzeb's co-authors include Mark N. Levine, Charles W. Francis, Mark R. Somerfield, Gary H. Lyman, Anna Falanga, Nicole M. Kuderer, Howard A. Liebman, Alok A. Khorana, David S. Mendelson and Ajay K. Kakkar and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Mohammad Jahanzeb

65 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

American Society of Clinical Oncology Guideline: Recommendations for Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer

2007 723 citations Mohammad Jahanzeb et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Mohammad Jahanzeb

Since Specialization

Citations

This map shows the geographic impact of Mohammad Jahanzeb's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mohammad Jahanzeb with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mohammad Jahanzeb more than expected).

Fields of papers citing papers by Mohammad Jahanzeb

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mohammad Jahanzeb. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mohammad Jahanzeb. The network helps show where Mohammad Jahanzeb may publish in the future.

Co-authorship network of co-authors of Mohammad Jahanzeb

This figure shows the co-authorship network connecting the top 25 collaborators of Mohammad Jahanzeb. A scholar is included among the top collaborators of Mohammad Jahanzeb based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mohammad Jahanzeb. Mohammad Jahanzeb is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Health-related quality of life in the randomized phase III trial of brigatinib vs crizotinib in advanced ALK inhibitor–naive ALK + non−small cell lung cancer (ALTA-1L) 2021 ·Lung Cancer ·M.R. García Campelo, Huamao Mark Lin, Yanyan Zhu, M. Pérol, Mohammad Jahanzeb, Sanjay Popat, Pingkuan Zhang, D. Ross Camidge	12
2	Response to Abemaciclib After 10 Lines of Therapy Including Palbociclib in Metastatic Breast Cancer: A Case Report With Literature Review 2020 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), Mohammad Jahanzeb	4
3	Immunotherapy Treatment Patterns and Outcomes Among ALK-Positive Patients With Non–Small-Cell Lung Cancer 2020 ·Clinical Lung Cancer ·Mohammad Jahanzeb, Huamao Mark Lin, Xiaoyun Pan, Yu Yin, Pia Baumann, Corey J. Langer	47
4	Treatment of anaplastic lymphoma kinase-positive lung adenocarcinoma with pemetrexed and carboplatin after crizotinib failure and significant liver dysfunction; a case report 2020 ·Cancer Treatment and Research Communications ·(unknown), (unknown), Mohammad Jahanzeb	0
5	De Novo Versus Recurrent HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry 2019 ·The Oncologist ·Debu Tripathy, Adam Brufsky, Melody Cobleigh, Mohammad Jahanzeb, Peter A. Kaufman, Ginny Mason, Joyce O’Shaughnessy, Hope S. Rugo, Sandra M. Swain, Denise A. Yardley, Laura Chu, Haocheng Li, Vincent Antao, Sara A. Hurvitz	45
6	PCN308 REAL-WORLD UTILIZATION OF BRIGATINIB IN PATIENTS WITH NON–SMALL CELL LUNG CANCER (NSCLC) 2019 ·Value in Health ·(unknown), Xiaoyun Pan, Peijie Hou, Hui Huang, Pia Baumann, Mohammad Jahanzeb	1
7	Developing a Predictive Model for Clinical Outcomes of Advanced Non-Small Cell Lung Cancer Patients Treated With Nivolumab 2017 ·Clinical Lung Cancer ·Wungki Park, Deukwoo Kwon, (unknown), Amrita Desai, Fernando Regla Vargas, Mohamed El Dinali, (unknown), Roy Elias, Young Kwang Chae, Dae Won Kim, (unknown), Adrian Ishkanian, Chukwuemeka Ikpeazu, Raja Mudad, Gilberto Lopes, Mohammad Jahanzeb	45
8	Clinical Outcomes in Elderly Patients with Advanced Non-small Cell Lung Cancer: Results from ARIES, a Bevacizumab Observational Cohort Study 2015 ·Clinical Oncology ·Agnieszka Woźniak, Michael P. Kosty, Mohammad Jahanzeb, Julie R. Brahmer, David R. Spigel, (unknown), Susan Fish, E. Dawn Flick, Sebastien Hazard, Thomas J. Lynch	21
9	Effectiveness and safety of post-induction phase bevacizumab treatment for patients with non-small-cell lung cancer: results from the ARIES observational cohort study 2015 ·Targeted Oncology ·Michael P. Kosty, Antoinette J. Wozniak, Mohammad Jahanzeb, Larry Leon, Susan Fish, Sebastien Hazard, Thomas J. Lynch	5
10	Safety and Effectiveness of Bevacizumab-Containing Treatment for Non–Small-Cell Lung Cancer: Final Results of the ARIES Observational Cohort Study 2014 ·Journal of Thoracic Oncology ·Thomas J. Lynch, David R. Spigel, Julie R. Brahmer, Neal Fischbach, Jennifer Garst, Mohammad Jahanzeb, Priya Kumar, Regina M Vidaver, Antoinette J. Wozniak, Susan Fish, E. Dawn Flick, Larry Leon, Sebastien Hazard, Michael P. Kosty	44
11	Modification and Implementation of NCCN Guidelines™ on Non–Small Cell Lung Cancer in the Middle East and North Africa Region 2010 ·Journal of the National Comprehensive Cancer Network ·Abdul Rahman Jazieh, (unknown), Ahmet Demirkazık, Rabab Gaafar, Fady Geara, (unknown), Jamal Khader, (unknown), (unknown), (unknown), (unknown), Mohammad Behgam Shadmehr, (unknown), (unknown), Mohammad Jahanzeb, David S. Ettinger	20
12	Development of cavitation while on bevacizumab (BV) therapy in patients (pts) with non-small cell lung cancer (NSCLC): Results from ARIES—A bevacizumab (BV) treatment observational cohort study (OCS) 2009 ·Journal of Clinical Oncology ·Michael P. Kosty, (unknown), (unknown), Mohammad Jahanzeb, Christine Chung, (unknown), (unknown), Thomas P. Lynch, (unknown)	2
13	Reducing the Risk for Breast Cancer Recurrence After Completion of Tamoxifen Treatment in Postmenopausal Women 2007 ·Clinical Therapeutics ·Mohammad Jahanzeb	10
14	Neoadjuvant docetaxel followed by adjuvant doxorubicin and cyclophosphamide in patients with stage III breast cancer 2005 ·Annals of Oncology ·William J. Gradishar, Suparna Wedam, Mohammad Jahanzeb, John K. Erban, Steven Limentani, (unknown), Steven R. Olsen, Sandra M. Swain	32
15	Trastuzumab-Based Combinations in Metastatic Breast Cancer: How to Make a Choice 2003 ·Clinical Breast Cancer ·Mohammad Jahanzeb	15
16	Phase II Trial of Weekly Vinorelbine and Trastuzumab as First-Line Therapy in Patients with HER2+ Metastatic Breast Cancer 2002 ·The Oncologist ·Mohammad Jahanzeb, Joanne Mortimer, Furhan Yunus, David Irwin, James L. Speyer, Alan J. Koletsky, Paula Klein, (unknown), (unknown)	98
17	Weekly herceptin with navelbine in chemonaïve patients with HER2 positive metastatic breast cancer: A phase II multicenter trial 2001 ·Breast Cancer Research and Treatment ·Mohammad Jahanzeb, Joanne Mortimer, F. Yunus, (unknown), (unknown), Alan J. Koletsky, Pamela Klein, (unknown), (unknown)	2
18	HER-2/neu expression in archival non-small cell lung carcinomas using FDA-approved Hercep test. 2000 ·PubMed ·Daniela Scheurle, Mohammad Jahanzeb, (unknown), (unknown), Ramaswamy Narayanan	50
19	Results of A trial with topotecan dose escalation and concurrent thoracic radiation therapy for locally advanced, inoperable nonsmall cell lung cancer 1996 ·International Journal of Radiation OncologyBiologyPhysics ·Mary V. Graham, Mohammad Jahanzeb, Carolyn M. Dresler, Joel D. Cooper, Bahman Emami, Joanne Mortimer	23
20	Multicenter phase II study of weekly oral vinorelbine for stage IV non-small-cell lung cancer. 1995 ·Journal of Clinical Oncology ·Everett E. Vokes, Richard K. Rosenberg, Mohammad Jahanzeb, John B. Craig, Richard J. Gralla, Chandra P. Belani, Stephen E. Jones, Joseph Bigley, John Hohneker	34

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact